ASB Consultores LLC Has $435,000 Position in Pfizer Inc. (NYSE:PFE)

ASB Consultores LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 17.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,558 shares of the biopharmaceutical company’s stock after selling 3,361 shares during the period. ASB Consultores LLC’s holdings in Pfizer were worth $435,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Bridges Investment Management Inc. increased its stake in shares of Pfizer by 81.9% during the 2nd quarter. Bridges Investment Management Inc. now owns 84,412 shares of the biopharmaceutical company’s stock worth $2,362,000 after purchasing an additional 38,012 shares during the last quarter. Callan Capital LLC boosted its holdings in Pfizer by 16.7% in the 2nd quarter. Callan Capital LLC now owns 17,845 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 2,551 shares during the period. Wealth Advisors of Tampa Bay LLC boosted its holdings in Pfizer by 2.7% in the 2nd quarter. Wealth Advisors of Tampa Bay LLC now owns 144,439 shares of the biopharmaceutical company’s stock valued at $4,041,000 after purchasing an additional 3,800 shares during the period. Trust Investment Advisors bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $1,259,000. Finally, Ieq Capital LLC lifted its holdings in shares of Pfizer by 15.6% during the 2nd quarter. Ieq Capital LLC now owns 224,636 shares of the biopharmaceutical company’s stock worth $6,285,000 after acquiring an additional 30,388 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on PFE shares. Barclays upped their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Wells Fargo & Company upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Trading Down 0.3 %

NYSE:PFE opened at $29.67 on Friday. The firm’s fifty day moving average is $29.35 and its 200-day moving average is $28.20. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $34.11. The firm has a market cap of $168.13 billion, a P/E ratio of -494.42, a P/E/G ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 EPS. Equities analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.66%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.